Literature DB >> 21631894

Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population.

Erik A Badings1, Lyanne Dyal, Lydia Schoterman, Dirk J A Lok, Ies Stoel, Martin N Gerding, Hertzel C Gerstein, Jan G P Tijssen.   

Abstract

BACKGROUND: To investigate whether the combination of HbA1c and fasting plasma glucose (FPG) can be used for the diagnosis of diabetes and impaired glucose tolerance (IGT) in people at high risk of cardiovascular disease (CVD).
METHODS: A cross-sectional study was performed on 2907 people at high risk of cardiovascular events but without a previous diagnosis of diabetes. Optimal cut-off points and the diagnostic potential of FPG, HbA1c, and their combination were determined.
RESULTS: The sensitivity of the usually applied FPG cut-off point of 7.0 mmol/L to diagnose diabetes mellitus was low (59.0%). Receiver operating characteristic (ROC) curve analysis indicated that the optimal cut-off points for the diagnosis of diabetes using FPG and HbA1c were 6.4 mmol/L (sensitivity 75.7%; specificity 77.5%; likelihood ratio 3.37) and 5.9% (41 mmol/mol; sensitivity 68.7%; specificity 67.1%; likelihood ratio 2.09), respectively. To diagnose IGT, the optimal cut-off points for FPG and HbA1c were 6.1 mmol/L (sensitivity 57.1%; specificity 57.9%) and 5.7% (39 mmol/mol; sensitivity 63.8%; specificity 60.3%), respectively. For diabetes, combining cut-off points for FPG and HbA1c identified four categories with likelihood ratios ranging from 5.59 to 0.21, and post-test probabilities between 69.3% and 7.8%. For IGT, likelihood ratios varied between 2.05 and 0.56, whereas post-test probabilities ranged from 84.0% to 58.8%.
CONCLUSIONS: Using FPG alone results in the underdiagnosis of glucometabolic abnormalities in people at high risk of CVD. Using an algorithm with both HbA1c and FPG improves the detection of diabetes, but not IGT, and could be easily implemented in patient care.
© 2011 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21631894     DOI: 10.1111/j.1753-0407.2011.00124.x

Source DB:  PubMed          Journal:  J Diabetes        ISSN: 1753-0407            Impact factor:   4.006


  4 in total

Review 1.  Marine-derived n-3 fatty acids therapy for stroke.

Authors:  Celia Gabriela Alvarez Campano; Mary Joan Macleod; Lorna Aucott; Frank Thies
Journal:  Cochrane Database Syst Rev       Date:  2022-06-29

Review 2.  Omega-3 fatty acids and cognitive function in women.

Authors:  Jennifer G Robinson; Nkechinyere Ijioma; William Harris
Journal:  Womens Health (Lond)       Date:  2010-01

3.  Marine-derived n-3 fatty acids therapy for stroke.

Authors:  Celia Gabriela Alvarez Campano; Mary Joan Macleod; Lorna Aucott; Frank Thies
Journal:  Cochrane Database Syst Rev       Date:  2019-06-26

4.  Protocol on a multicentre statistical and economic modelling study of risk-based stratified and personalised screening for diabetes and its complications in India (SMART India).

Authors:  Sobha Sivaprasad; Rajiv Raman; Ramachandran Rajalakshmi; Viswanathan Mohan; Mohan Deepa; Taraprasad Das; Kim Ramasamy; A Toby Prevost; Raphael Wittenberg; Gopalakrishnan Netuveli; Gopal Lingam; Wasim Hanif; Radha Ramakrishnan; Jayashree Ramu; Janani Surya; Dolores Conroy
Journal:  BMJ Open       Date:  2020-12-12       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.